Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION (Details) - Segments Information

v3.10.0.1
SEGMENT INFORMATION (Details) - Segments Information - USD ($)
 12 Months Ended
Oct. 31, 2018
Oct. 31, 2017
Segment Reporting Information [Line Items]    
Net Income (Loss) $ (14,243,084) $ (5,008,991)
Operating costs and expenses 15,401,558 6,438,084
Less non-cash share based compensation (8,895,614) (1,676,772)
Operating costs and expenses 6,505,944 4,761,312
Total Assets 6,448,542 8,812,416
Operating Segments [Member] | Cancer Detection Platform [Member]    
Segment Reporting Information [Line Items]    
Net Income (Loss) (5,920,457) (5,014,164)
Operating costs and expenses 2,431,810 3,659,280
Total Assets 2,545,803 5,684,915
Operating Segments [Member] | CAR-T Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net Income (Loss) (7,073,322) (504,405)
Operating costs and expenses 2,120,614 342,064
Total Assets 2,157,359 521,326
Operating Segments [Member] | Patent Licensing [Member]    
Segment Reporting Information [Line Items]    
Net Income (Loss) (1,249,305) 509,578
Operating costs and expenses 1,953,520 759,968
Total Assets $ 1,745,380 $ 2,606,175